Noninvasive measurement of tumor heterogeneity in head and neck squamous cell carcinoma

Noninvasive Intratumor Heterogeneity Evaluation in HNSCC With Multi-omics Insights and Therapeutic Targets

This project tests an imaging-based model to see if noninvasive scans can predict treatment response and prognosis for people with head and neck squamous cell carcinoma.

Quick facts

• Study type: Observational
• Enrollment: 700 (estimated)
• Ages: 15 Years to 89 Years
• Sex: All
• Sponsor: First Affiliated Hospital of Chongqing Medical University (Academic / other)
• Drugs / interventions: chemotherapy
• Locations: 1 site (Chongqing)
• Trial ID: NCT07027280 on ClinicalTrials.gov

What this trial studies

This observational study builds an imaging analysis model to quantify intratumoral heterogeneity from patients' preoperative scans. Imaging features will be integrated with clinical, pathological, transcriptomic, and metabolomic data to produce a multi-omics map of tumor heterogeneity. The team will test whether the imaging-derived heterogeneity model can stratify patients by treatment efficacy and prognosis and will use pathology and sequencing to explore underlying mechanisms. Eligible patients must have complete clinical, imaging, and pathological data and must not have received chemotherapy or radiotherapy before surgery.

Who should consider this trial

Good fit: Ideal candidates are people with pathologically confirmed head and neck squamous cell carcinoma who have complete preoperative imaging, clinical, and pathological data, available follow-up, and no prior chemotherapy or radiotherapy before surgery.

Not a fit: Patients who received chemotherapy or radiotherapy before surgery, have poor-quality or too-small tumors on imaging, or have other concurrent malignancies are unlikely to benefit from this protocol.

Why it matters

Potential benefit: If successful, this approach could provide a noninvasive way to personalize treatment choices and better predict outcomes for patients with head and neck cancer.

How similar studies have performed: Radiomics and imaging-based heterogeneity approaches have shown promising predictive results in cancer, but full integration with multi-omics sequencing remains relatively novel and not yet widely validated.

Eligibility criteria

Inclusion Criteria:

Pathologically confirmed head and neck squamous cell carcinoma (HNSCC). Complete clinical, imaging, and pathological data. Available complete follow-up information.

Exclusion Criteria:

Patients who received chemotherapy or radiotherapy before surgery. Poor image quality. Tumors too small to be easily identified. History of other concurrent malignant tumors.

Where this trial is running

Chongqing

• The First Affiliated Hospital of Chongqing Medical University — Chongqing, China (Recruiting)

Study contacts

• Study coordinator: xinwei Chen

Conditions Head and Neck Cancer